# AUROPHARMA (AUROPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/auropharma

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,734
- Change: +2.60%
- As of: 2026-09-18
- 1D return: +2.60%
- 5D return: +3.93%
- 1M return: +7.84%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, AUROPHARMA is trading at ₹1734.0, with a generally bullish technical stance across multiple timeframes. Daily, weekly, and monthly indicators show the price above key moving averages and the Supertrend, suggesting an uptrend is in place. The daily timeframe shows an ADX of 23.29, indicating a developing trend, with the plus DI (28.12) above the minus DI (14.62). Similarly, the weekly and monthly timeframes exhibit stronger trending signals with higher ADX values (40.72 and 29.33, respectively) and bullish Supertrend directions. Recent market activity shows a mix of positive and neutral attention events over the past 30 days. The stock is positioned at the upper end of its recent trading range, with a distance of 0.0% from the available high and 0.7% from the available low in its 20-period range. Annualized volatility stands at 29%, with an Average True Range (ATR) of 2.36% of the current price.

Key patterns observed include an active Hammer pattern on the monthly chart and an active Outside Bar on the weekly chart, both as of September 18, 2026. These patterns, alongside the bullish price action across timeframes, suggest potential for continued upward momentum, though the proximity to resistance levels warrants attention. The nearest identified support is ₹1730.4, which is very close to the current price, followed by ₹1710.2. The nearest resistance is noted at ₹1768.5.

- The stock is trading above its 20-day, 50-day, and 200-day Simple Moving Averages (SMA) and Exponential Moving Averages (EMA) on the daily chart.
- The Supertrend indicator is bullish across daily, weekly, and monthly timeframes.
- Nearest support levels are ₹1730.4 and ₹1710.2.
- Nearest resistance level is ₹1768.5.
- Active monthly Hammer and weekly Outside Bar patterns were observed on September 18, 2026.

- Hammer
- Outside Bar
- Bullish Engulfing Reversal
- Bearish Engulfing Reversal
- Inside Bar
- Doji

### News Context

In the week ending September 18, 2026, Aurobindo Pharma was featured in analyst reports highlighting potential upside. JM Financial maintained a Buy rating on the company on September 16, 2026, citing expectations of stronger earnings growth, business diversification, and new product launches. They projected up to a 28% upside over the next 12 months. Separately, on September 18, 2026, a financial news outlet included Aurobindo Pharma among stocks to trade, listing key levels and target prices, though specific details were not provided in the summary. The broader market saw pharma shares snapping a five-day losing streak on September 17, 2026, amidst cautious investor sentiment due to potential US interest rate hikes.

- JM Financial maintained a Buy rating on Aurobindo Pharma on September 16, 2026, with a 12-month upside projection of up to 28%.
- JM Financial's positive outlook is based on expected stronger earnings growth, business diversification, and new product launches.
- A financial news report on September 18, 2026, identified Aurobindo Pharma as a stock to trade, mentioning key levels and target prices.
- Pharma shares, including Aurobindo Pharma, ended a five-day losing streak on September 17, 2026.

- Kotak Bank, Auro Pharma, GE Vernova T&D: Top stocks to trade — Key levels, target price & stop loss
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Taking Stock: Market snaps 2-day losing streak; Nifty above 23,200, Sensex gains 332 pts ahead of FOMC decision
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
- Quant Mid Cap Fund exits ICICI Bank, 2 others and adds 5 stocks in August

### What Changed

As of September 18, 2026, Aurobindo Pharma (AUROPHARMA) on the NSE has seen a recent price increase, trading at ₹1734.0 compared to its previous price of ₹1690.0. This shift occurred amidst news that included Aurobindo Pharma among stocks identified for trading, with specific mention of key levels, target prices, and stop losses. The company's profile as listed on the NSE remains unchanged.

- On September 18, 2026, Aurobindo Pharma's stock price was ₹1734.0.
- The stock price on the preceding observation date was ₹1690.0.
- News on September 18, 2026, highlighted Aurobindo Pharma as a stock for trading, referencing target prices and stop losses.
- Aurobindo Pharma is listed on the NSE.

- Kotak Bank, Auro Pharma, GE Vernova T&D: Top stocks to trade — Key levels, target price & stop loss

### Official Filings

Aurobindo Pharma Limited has received final approval from the US Food and Drug Administration (USFDA) on September 15, 2026, for its Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg. This marks the company's entry into complex respiratory therapies with its first metered-dose inhaler product, slated for launch in upcoming quarters. The US market for this product was valued at US$301 million for the twelve months ending July 2026. Additionally, the USFDA completed an inspection of Apitoria Pharma Private Limited's Unit-II API facility in Telangana on September 15, 2026, with one procedural observation noted, to which the company will respond. The company also has several investor and analyst meetings scheduled between September 17 and September 22, 2026, to discuss business updates, with assurances that no unpublished price-sensitive information will be disclosed.

- On September 15, 2026, Aurobindo Pharma received USFDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg.
- The US market for this product was US$301 million for the twelve months ending July 2026.
- On September 15, 2026, the USFDA inspection of Apitoria Pharma Private Limited's Unit-II API facility concluded with one procedural observation.
- Aurobindo Pharma is scheduled to participate in multiple investor and analyst meetings from September 17 to September 22, 2026.

- Aurobindo Pharma Limited has informed the Exchange regarding a press release dated September 15, 2026, titled "Aurobindo Pharma receives USFDA Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg". |SUBJECT: Press Release
- Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company. |SUBJECT: General Updates
- Aurobindo Pharma Limited has informed the Exchange about Acquisition |SUBJECT: Acquisition
- AUROBINDO PHARMA LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire) |SUBJECT: Acquisition (including agreement to acquire)-XBRL
- AUROBINDO PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Aurobindo Pharma Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### Fundamentals

Aurobindo Pharma's reported results show a recent upward trend in revenue, reaching ₹9,150.35 crore in Q1 FY2026-27. This revenue growth has been accompanied by an increase in expenses, which rose to ₹7,857.77 crore in the same period. Profit Before Tax (PBT) saw a notable increase to ₹1,516.63 crore in Q1 FY2026-27, up from ₹1,338.15 crore in Q3 FY2025-26. Consequently, the net profit, or Profit Loss For Period, also grew to ₹1,032.03 crore in Q1 FY2026-27. Basic Earnings Per Share (EPS) followed this trend, increasing to ₹17.86 per share in Q1 FY2026-27. However, Comprehensive Income for the period showed some volatility, declining to ₹985.16 crore in Q1 FY2026-27 after a significant jump to ₹1,711.40 crore in Q4 FY2025-26. The company's operating performance appears to be improving, with revenue and net profit showing sequential growth.

- Revenue From Operations increased sequentially from ₹8,645.90 crore in Q3 FY2025-26 to ₹9,150.35 crore in Q1 FY2026-27.
- Profit Loss For Period grew from ₹909.80 crore in Q3 FY2025-26 to ₹1,032.03 crore in Q1 FY2026-27.
- Basic Earnings Per Share from Continuing and Discontinued Operations rose to ₹17.86 per share in Q1 FY2026-27, up from ₹15.67 per share in Q3 FY2025-26.
- Comprehensive Income For The Period was ₹985.16 crore in Q1 FY2026-27, a decrease from ₹1,711.40 crore in Q4 FY2025-26.
- Profit Before Tax increased to ₹1,516.63 crore in Q1 FY2026-27, compared to ₹1,338.15 crore in Q3 FY2025-26.

### Bull Case

Aurobindo Pharma's technical indicators suggest a positive trend across multiple timeframes. The daily, weekly, and monthly trends are all indicated as bullish, with the Supertrend indicator showing a bullish direction on all three. The closing price of ₹1734.0 on September 18, 2026, is above the 20-day and 50-day Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs) for the daily timeframe. The stock has also shown significant positive returns over the past year, with a 1-year return of 0.54 and a Year-to-Date (YTD) return of 0.45.

- The Supertrend indicator is bullish across daily, weekly, and monthly timeframes as of September 18, 2026.
- On the daily chart, the closing price of ₹1734.0 on September 18, 2026, is above the 20-day EMA (₹1664.04) and 50-day EMA (₹1619.92).
- The stock has delivered a 1-year return of 0.54 and a YTD return of 0.45 as of September 18, 2026.
- External analysts at JM Financial have retained a 'Buy' rating, citing expectations of stronger earnings growth, business diversification, and new product launches, with an implied upside potential of up to 28% over the next 12 months.

- Kotak Bank, Auro Pharma, GE Vernova T&D: Top stocks to trade — Key levels, target price & stop loss
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Taking Stock: Market snaps 2-day losing streak; Nifty above 23,200, Sensex gains 332 pts ahead of FOMC decision
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
- Quant Mid Cap Fund exits ICICI Bank, 2 others and adds 5 stocks in August

### Bear Case

While recent market commentary indicates potential upside for Aurobindo Pharma, a review of its technical indicators reveals some cautionary signals. The company's stock has experienced significant price appreciation over the past year, with a 1-year return of 0.54. However, its maximum drawdown stands at -0.24, suggesting periods of notable decline. The annualized volatility is 0.29, and downside deviation is 0.18, indicating a degree of price fluctuation that investors should monitor.

- Aurobindo Pharma's stock has a maximum drawdown of -0.24.
- The annualized volatility for the stock is 0.29.
- The downside deviation is reported at 0.18.

- Kotak Bank, Auro Pharma, GE Vernova T&D: Top stocks to trade — Key levels, target price & stop loss
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Taking Stock: Market snaps 2-day losing streak; Nifty above 23,200, Sensex gains 332 pts ahead of FOMC decision
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
- Quant Mid Cap Fund exits ICICI Bank, 2 others and adds 5 stocks in August

### FAQs

**What recent regulatory approvals has Aurobindo Pharma received, and what is their significance?**

On September 15, 2026, Aurobindo Pharma announced it received final approval from the US FDA for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg. This marks the company's entry into metered-dose inhaler products and its expansion into complex respiratory therapies. The product, to be manufactured at a North Carolina facility, is a generic equivalent of QVAR®, which had a US market size of approximately US$301 million for the twelve months ending July 2026. Additionally, on the same date, the US FDA completed an inspection of Apitoria Pharma Private Limited's (a subsidiary) API facility in Telangana, which concluded with one procedural observation.

**What is the recent analyst sentiment regarding Aurobindo Pharma's stock?**

JM Financial maintained a 'Buy' rating on Aurobindo Pharma, projecting up to a 28% upside over the next 12 months. The brokerage cited expectations of stronger earnings growth, business diversification, and new product launches as supporting factors for this view.

**How has Aurobindo Pharma's stock performed over different periods, and what are the current technical indicators suggesting?**

As of September 18, 2026, Aurobindo Pharma has shown positive returns across various periods, including a 54% return over the last year and a 45% year-to-date return. Technical indicators on a daily and weekly basis suggest a 'bullish' trend, with the closing price of ₹1734.0 on September 18, 2026, trading above its 20-day and 50-day Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs). The Supertrend indicator also signals a bullish direction on both daily and monthly timeframes.

**What significant corporate actions or events has Aurobindo Pharma recently announced?**

Aurobindo Pharma has announced acquisitions, with details provided in filings on September 12, 2026. The company also scheduled an in-person analyst meeting with ICICI Securities in Hyderabad for September 17, 2026, to discuss business updates.

- Kotak Bank, Auro Pharma, GE Vernova T&D: Top stocks to trade — Key levels, target price & stop loss
- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Taking Stock: Market snaps 2-day losing streak; Nifty above 23,200, Sensex gains 332 pts ahead of FOMC decision
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?
- Quant Mid Cap Fund exits ICICI Bank, 2 others and adds 5 stocks in August
- Aurobindo Pharma Limited has informed the Exchange regarding a press release dated September 15, 2026, titled "Aurobindo Pharma receives USFDA Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg". |SUBJECT: Press Release
- Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company. |SUBJECT: General Updates
- Aurobindo Pharma Limited has informed the Exchange about Acquisition |SUBJECT: Acquisition
- AUROBINDO PHARMA LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire) |SUBJECT: Acquisition (including agreement to acquire)-XBRL
- AUROBINDO PHARMA LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,672.1
- Risk regime: Price Risk Currently Contained

### Support levels
- 1401
- 1186.78125
- 1147.465625

### Resistance levels
- 1768.5000000000002

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +2.60% |
| return_10 | +5.91% |
| return_1m | +5.41% |
| return_1y | +53.60% |
| return_20 | +7.84% |
| return_3m | +20.11% |
| return_5 | +3.93% |
| return_6m | +36.64% |
| return_since_start | +28.14% |
| return_ytd | +45.35% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -24.46% |
| annualized_volatility | +28.54% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Profit Growth Outpaces Revenue While Comprehensive Income Declines

Aurobindo Pharma reported a 3.35% sequential rise in revenue and a 17.29% jump in profit before tax for the quarter ended 30 June 2026, as expenses grew more slowly than sales. Net profit increased 12.1% from the prior quarter and the effective tax rate moved higher. However, comprehensive income fell sharply because other comprehensive income swung from a large gain to a small loss.

## Revenue

Revenue from operations stood at ₹9,150.35 crore, up 3.35% from ₹8,853.34 crore in the preceding quarter (Q4 FY2026) and 16.3% higher than ₹7,868.14 crore in the same quarter a year earlier. The ₹297.01 crore sequential gain was accompanied by even stronger profit growth, reflecting a slower increase in total expenses.

## Profitability

Profit Before Tax (PBT) reached ₹1,516.63 crore, a sequential increase of 17.29% and a year-over-year rise of 25.87%. Total expenses rose by only 2.35% to ₹7,857.77 crore, a pace well below the 3.35% revenue growth. This drove the pre-tax margin to 16.58% from 14.61% in the prior quarter.

Net profit for the period was ₹1,032.03 crore, up 12.1% from ₹920.84 crore in Q4 FY2026. Basic earnings per share climbed to ₹17.86 from ₹15.86, a 12.61% sequential increase, and were 25.77% higher than the ₹14.20 recorded in the year-ago quarter.

## Comprehensive Income

While net profit grew, comprehensive income for the period fell to ₹985.16 crore, a decline of 42.44% from ₹1,711.40 crore in the previous quarter. The difference arises from other comprehensive income (OCI), which includes items like foreign‑currency translation adjustments and is not part of net profit. In Q4 FY2026, OCI added around ₹790 crore; in the current quarter, it subtracted roughly ₹47 crore. The swing in these non‑operating items caused comprehensive income to trail net profit by a wide margin.

## Tax and Financing Costs

Tax expense rose to ₹483.06 crore, a 30.64% sequential increase and 26.26% higher than the year‑ago quarter. The effective tax rate moved to approximately 31.9%, up from 28.6% in Q4 FY2026 but roughly in line with the 31.8% recorded a year earlier. Finance costs edged up 3.51% to ₹101.66 crore from ₹98.21 crore.

## Management Commentary

Management expressed confidence in the company's trajectory, citing a strong start to FY27 with 16.3% YoY revenue growth to INR 9,150 Cr, driven by volume gains and new launches across all key geographies. They noted that while the global operating environment remains dynamic, the resilient business model, expanding capabilities, and strategic investments position the company well to achieve long-term growth objectives.

Strategically, the company is advancing its biosimilars pipeline through CuraTeQ, with key filings in Europe and imminent USFDA submissions, and expanding biologics contract manufacturing via TheraNym, anchored by a long-term partnership with MSD. Additionally, the board approved a merger of three injectable-focused subsidiaries to simplify the group structure and reduce costs.

## Key Takeaway

Revenue and profitability both advanced in the quarter, with profit growth outstripping sales growth and pre‑tax margins expanding. At the same time, a sharp reversal in other comprehensive income caused comprehensive income to fall substantially despite higher net profit. The quarter illustrates that while operational earnings strengthened, changes in non‑operating items can heavily influence the total equity measure.

### Ratios

## Official filings

- 2026-09-15 — Press Release: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_15092026130257_LtrToSEsPressReleaseUSFDAapproval15092026.pdf)
- 2026-09-15 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_15092026181104_LtrToSEsApitoriaUnit2USFDA15092026.pdf)
- 2026-09-12 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_12092026124039_LtrToSEsA1Biochem12092026.pdf)
- 2026-09-12 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_934_WebXMLFile_20260912_125348379.xml)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_934_WebXMLFile_20260911_131913278.xml)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_934_WebXMLFile_20260911_131940375.xml)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_11092026130527_LtrToSEsICICIInvestorMeet11092026.pdf)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_11092026130740_LtrToSEsKotakInvestorMeet11092026.pdf)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_11092026163848_LtrToSEsEmkayInvestorMeet11092026.pdf)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_11092026164251_LtrToSEsJPMorganInvestorMeet11092026.pdf)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_11092026164116_LtrToSEsBankofAmericaInvestorMeet11092026.pdf)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_934_WebXMLFile_20260911_164949976.xml)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_934_WebXMLFile_20260911_164942347.xml)
- 2026-09-11 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_11092026173035_LtrToSEsApitoriaUnitIVUSFDAInspection11092026.pdf)
- 2026-09-03 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_03092026110936_LtrToSEsPaperAdIEPF03092026.pdf)
- 2026-09-01 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_934_WebXMLFile_20260901_102116512.xml)
- 2026-09-01 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_01092026100944_LtrToSEsAvogent01092026.pdf)
- 2026-08-31 — Press Release: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_31082026100851_LtrtoSEsLannetPR31082026.pdf)
- 2026-08-28 — Regulatory Filing: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/RESULT_VOTING_1718829_28082026031911_WEB.xml)
- 2026-08-28 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_28082026151422_LtrToSEs39thAGMvotingResults28082026.pdf)
- 2026-08-28 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_28082026153621_LtrToSEsApitoriaUnitVIUSFDA28082026.pdf)
- 2026-08-27 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_27082026183138_LtrToSEs39thAGMproceedings27082026.pdf)
- 2026-08-25 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_25082026143334_LtrToSEsInvestorMeet25082026.pdf)
- 2026-08-25 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_934_WebXMLFile_20260825_144949154.xml)
- 2026-08-25 — Generic Announcement: Aurobindo Pharma Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/AUROPHARMA_25082026172321_LtrToSEsGoldmanInvestorMeet25082026.pdf)

## News and market events

- 2026-09-18 — BUSINESSTODAY: **Kotak Bank, Auro Pharma, GE Vernova T&D: Top stocks to trade — Key levels, target price & stop loss** — Stocks to buy, Stock picks, Stocks to trade, trading views, Kotak Mahindra Bank,, Aurobindo Pharma, GE Vernova T&D India, Kotak Bank shares, Auro Pharma shares, GE Vernova T&D shares, Kotak Bank share price, Auro Pharma share price, GE Vernova T&D share price, Kotak Bank stock price, Auro Pharma stock price, GE Vernova T&D stock price, Kotak Bank target price, Auro Pharma target price, GE Vernova T&D target price — [Source](https://www.businesstoday.in/markets/stocks/story/kotak-bank-auro-pharma-ge-vernova-td-top-stocks-to-trade-key-levels-target-price-stop-loss-556322-2026-09-18)
- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-16 — MONEYCONTROL: **Taking Stock: Market snaps 2-day losing streak; Nifty above 23,200, Sensex gains 332 pts ahead of FOMC decision** — Stock Market Today,Taking Stock,Sensex,Nifty,Market Today,Sensex Today, Nifty Today,Stock Market Today,India Stock Market Today,Share Market Today — [Source](https://www.moneycontrol.com/news/business/markets/taking-stock-market-snaps-2-day-losing-streak-nifty-above-23-200-sensex-gains-332-pts-ahead-of-fomc-decision-14031105.html)
- 2026-09-16 — Economic Times: **JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?** — JM Financial retained Buy ratings on Dr Reddys Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The brokerage expects stronger earnings growth, business diversification and new product launches to support both drugmakers. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/jm-financial-sees-up-to-28-upside-in-dr-reddys-and-aurobindo-pharma-should-you-buy/articleshow/134283456.cms)
- 2026-09-16 — Economic Times: **Quant Mid Cap Fund exits ICICI Bank, 2 others and adds 5 stocks in August** — Quant Mid Cap Fund exited ICICI Bank, Ambuja Cements and L&T Technology Services in August, while adding six stocks including IDBI Bank, Concor and Sona BLW Precision Forgings. The fund also increased exposure to three stocks and maintained holdings in 16 stocks. — [Source](https://economictimes.indiatimes.com/mf/analysis/quant-mid-cap-fund-exits-icici-bank-2-others-and-adds-5-stocks-in-august/articleshow/134280258.cms)
- 2026-09-16 — MONEYCONTROL: **Price Action: Saatvik Green Energy rises 5% on order win worth Rs 1,041cr; Aurobindo Pharma down 2% on USFDA observation** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/stocks/price-action-saatvik-green-energy-rises-5-on-order-win-worth-rs-1-041cr-aurobindo-pharma-down-2-on-usfda-observation-14030713.html)
- 2026-09-16 — BUSINESSTODAY: **Top stocks in news: Groww, Kanohar, BHEL, Glass Wall, Auro Pharma, GMR Airports, Prasol, NBCC** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Groww, Kanohar Electricals, Bharat Heavy Electricals, BHEL, Glass Wall Systems (India), Aurobindo Pharma, GMR Airports, Prasol Chemicals, NBCC (India), Tata Communications, Blue Star, Billionbrains Garage Ventures, Saatvik Green Energy, Sunshine Pictures, India Pesticides, Sonata Software, VIP Industries — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-groww-kanohar-bhel-glass-wall-auro-pharma-gmr-airports-prasol-nbcc-555749-2026-09-16)
- 2026-09-16 — MONEYCONTROL: **Aurobindo Pharma shares in focus after USFDA issues one observation for Telangana facility** — Aurobindo Pharma,Aurobindo Pharma share price,Aurobindo Pharma share price live today — [Source](https://www.moneycontrol.com/news/business/markets/aurobindo-pharma-shares-in-focus-after-usfda-issues-one-observation-for-telangana-facility-14030516.html)
- 2026-09-15 — The Hindu: **U.S. FDA issues observation to Aurobindo Pharma arm’s API unit** — U.S. FDA cites Aurobindo Pharma's API unit in Hyderabad with a procedural observation following a recent inspection. — [Source](https://www.thehindu.com/business/industry/us-fda-issues-observation-to-aurobindo-pharma-arms-api-unit/article71469185.ece)
- 2026-09-15 — The Hindu: **Aurobindo Pharma wins U.S. FDA approval for generic asthma inhaler** — Aurobindo Pharma receives U.S. FDA approval for a generic asthma inhaler, expanding into complex respiratory therapies. — [Source](https://www.thehindu.com/business/industry/aurobindo-pharma-wins-us-fda-approval-for-generic-asthma-inhaler/article71469168.ece)
- 2026-09-15 — Mint: **Top stocks in focus tomorrow: Investors must watch NBCC, BHEL, Bharat Forge shares on Wed, 16 Sept | Triggers** — On September 16, investors will monitor companies such as Tata Communications and Aurobindo Pharma due to various business updates, including new product launches, joint ventures, and settlement agreements.  — [Source](https://www.livemint.com/market/top-stocks-in-focus-tomorrow-investors-must-watch-nbcc-bhel-bharat-forge-shares-on-wed-16-sept-triggers-11789478026874.html)
- 2026-09-15 — BUSINESS: **Shares tumble as rising oil prices and bond yields intensify pressure** — The key equity benchmarks ended sharply lower on Tuesday, reversing early gains. Rising crude oil prices and higher US Treasury yields weighed on sentiment. The sell-off intensified as investors awaited the US Federal Reserve's policy decision on Wednesday. The Fed is widely expected to raise interest rates by 25 basis points. — [Source](https://www.business-standard.com/markets/capital-market-news/shares-tumble-as-rising-oil-prices-and-bond-yields-intensify-pressure-126091500871_1.html)
- 2026-09-15 — BUSINESS: **Sensex settles 778 pts lower; Nifty ends below 23,150** — As per provisional closing data, the S&P BSE Sensex tanked 777.94 points or 1.04% to 74,003.82. The Nifty 50 index lost 279.50 points or 1.19% to 23,118.60. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-settles-778-pts-lower-nifty-ends-below-23-150-126091500741_1.html)
- 2026-09-15 — BUSINESS: **Aurobindo Pharma receives USFDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol** — Aurobindo Pharma announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg, a generic equivalent of QVAR Inhalation Aerosol 40 mcg and 80 mcg, marketed by Teva Branded Pharmaceutical Products R&D LLC. — [Source](https://www.business-standard.com/markets/capital-market-news/aurobindo-pharma-receives-usfda-approval-for-beclomethasone-dipropionate-hfa-inhalation-aerosol-126091500646_1.html)
- 2026-09-15 — CNBC-TV18: **Aurobindo Pharma gets US FDA nod to sell first metered-dose asthma inhaler in US** — Aurobindo Pharma has received final US FDA approval for its first metered-dose inhaler, used to manage asthma symptoms and improve breathing. — [Source](https://www.cnbctv18.com/market/aurobindo-pharma-gets-us-fda-nod-to-sell-first-metered-dose-asthma-inhaler-in-us-19990888.htm)
- 2026-09-15 — BUSINESS: **Stock Alert: Lalithaa Jewellery Mart, HDFC Bank, KEC International, Aurobindo Pharma** — Securities in F&O Ban: — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-lalithaa-jewellery-mart-hdfc-bank-kec-international-aurobindo-pharma-126091500114_1.html)
- 2026-09-15 — MONEYCONTROL: **Moneycontrol Pro Market Outlook | All eyes on crude, Fed, and West Asia** — stocks, trading, markets, MARKET OUTLOOK — [Source](https://www.moneycontrol.com/news/business/markets/moneycontrol-pro-market-outlook-all-eyes-on-crude-fed-and-west-asia-14029681.html)
- 2026-09-15 — BUSINESSTODAY: **Top stocks in news: HDFC Bank, DRL, Solar Industries, Sun Pharma, TVS Motor, Pranav, Cochin Shipyard** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, HDFC Bank, Dr Reddys Laboratories, Solar Industries, Sun Pharmaceuticals Industries, TVS Motor Company, Pranav Constructions, Cochin Shipyard, KEC International, Raymond, Piramal Finance, Uno Minda, Greenply Industries, Strides Pharma Science, WeWork India Management, Indiabulls, Raghav Productivity Enhancers — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-hdfc-bank-drl-solar-industries-sun-pharma-tvs-motor-pranav-cochin-shipyard-555479-2026-09-15)
- 2026-09-15 — MONEYCONTROL: **Moneycontrol Pro Market Outlook | All eyes on crude oil, Fed, and West Asia** — outlook, markets, market outlook, pro market outlook — [Source](https://www.moneycontrol.com/news/business/markets/moneycontrol-pro-market-outlook-all-eyes-on-crude-oil-fed-and-west-asia-14029184.html)
- 2026-09-15 — Economic Times: **Stocks in news: Tata Group stocks, HDFC Bank, Coforge, HFCL, Sun Pharma and Varun Beverages** — On September 11, Indian stock markets experienced a remarkable bounce back after an initial dip at opening. Key index heavyweights attracted selective buying, which limited the days overall losses. Major players like HDFC Bank and IT sectors remained in focus amid relevant corporate announcements. Additionally, SEBI's discussion paper regarding the Closing Auction Session received input on five critical areas. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-hdfc-bank-coforge-hfcl-sun-pharma-and-varun-beverages/articleshow/134245046.cms)
- 2026-09-11 — CNBC-TV18: **Aurobindo Pharma gets zero observations from US FDA inspection at Andhra Pradesh facility** — Shares of Aurobindo Pharma Ltd ended at ₹1,675.45, up by ₹6.45, or 0.39%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/aurobindo-pharma-share-price-gets-zero-observations-from-us-fda-inspection-at-andhra-pradesh-facility-19989566.htm)
- 2026-09-06 — Mint: **RPG Life Sciences bets on China-plus 1, goes on an API buying spree | Company Business News** — The Harsh Goenka group is spending to build a drug-ingredients business, betting that the world's push to rely less on China will favour Indian makers. — [Source](https://www.livemint.com/companies/rpg-life-sciences-bets-on-china-plus-1-goes-on-an-api-buying-spree-pharma-healthcare-medicine-generic-11788660657183.html)
- 2026-09-02 — Mint: **Bajaj Auto to Info Edge - Jay Thakkar suggests 3 stocks to buy or sell for short-term in F&O segment | Stock Market News** — Indian equity indices are set to open muted on September 2, influenced by high crude oil prices and weak global cues. Nifty 50 ended below 24,100, with technical indicators suggesting cautious trading ahead. Analysts recommend specific stocks for futures trading based on recent market trends. — [Source](https://www.livemint.com/market/stock-market-news/bajaj-auto-to-info-edge-jay-thakkar-suggests-3-stocks-to-buy-or-sell-for-short-term-in-f-o-segment-11788316113751.html)
- 2026-09-01 — Mint: **Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 1 September 2026** — Indian stock indices Sensex and Nifty 50 are expected to open flat to negative on 1 Sept, influenced by weak global cues. Previous session saw Nifty close below 24,100 with lower momentum. Analysts suggest broader trading range with stocks like Sona BLW and Aurobindo Pharma recommended for buying. — [Source](https://www.livemint.com/market/stock-market-news/shares-to-buy-or-sell-chandan-taparia-of-motilal-oswal-recommends-three-stocks-to-buy-today-1-september-2026-11788226667822.html)
- 2026-08-31 — The Hindu: **Aurobindo arm Lannett launches generic of GSK’s drug in U.S.** — Aurobindo's Lannett launches a generic version of GSK’s Advair Diskus in the U.S., expanding its inhalation product portfolio. — [Source](https://www.thehindu.com/business/industry/aurobindo-arm-lannett-launches-generic-of-gsks-drug-in-us/article71411529.ece)

## Business profile

**Strategic vision:** Develops, manufactures, and commercializes generic pharmaceuticals and APIs.

### Business segments
- **North America (APUSA):** Aurobindo Pharma USA Inc (APUSA) is the sales and marketing arm in the US, distributing oral solid dosages and other products through various subsidiaries.
- **Europe:** Aurobindo Pharma operates a full-fledged sales infrastructure in 10 European countries, offering a product portfolio covering various therapeutic segments.
- **Specialty Products (Eugia Pharma Specialities Ltd.):** Eugia Pharma Specialities Ltd. is a subsidiary specializing in general injectables and oncology products, operating globally with multiple manufacturing facilities.
- **Research and Development:** Aurobindo Pharma has a strong R&D focus with 9 centers dedicated to enhancing patient impact through continuous research.

### Competitive strengths
- Global regulatory approvals for manufacturing facilities
- In-house API manufacturing capabilities
- Extensive global commercial infrastructure

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.25%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.78%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.80%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +2.21%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — +0.12%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/auropharma
Markdown representation: https://faxioms.com/stocks/auropharma?render=md